To validate the value of the risk score established in this study for anti-PD-L1 urothelial carcinoma, we utilized the “IMvigor210CoreBiologies” package to acquire 348 transcriptomes and corresponding clinical data from an IMvigor210-treated metastatic urothelial carcinoma cohort. This evidence concerns the gene CD274 and urothelial carcinoma.